The receptor for hyaluronic acid-mediated motility (RHAMM) is a tumor-associated antigen in chronic lymphocytic leukemia (CLL). CD8
Introduction
Chronic lymphocytic leukemia (CLL) is a common incurable hematological malignancy in the Western hemisphere. 1 Although several novel therapeutic approaches have entered the clinic and show high response rates in patients with CLL, most of them do not prolong overall survival, 2, 3 which strongly depends on a number of prognostic factors. 4, 5 Therefore, novel therapeutic options are desirable, especially for patients bearing negative prognostic markers such as cytogenetic aberrations (del17p and del11q), 6 unmutated IgVH gene status 7 or high ZAP-70 expression. 8 The clinical course of disease is heterogeneous. Two-thirds of CLL patients experience chronic disease, suggesting that some control over tumor burden exists. Moreover, half of those patients will never require treatment and, in some cases, spontaneous remission occurs. 1 Further, results from bone marrow transplantation, 9 as well as remission phenomena after viral infection, 10 suggest that CLL might be targeted effectively by T cell-based immunotherapy.
The receptor for hyaluronic acid-mediated motility (RHAMM) is involved in mitotic spindle apparatus formation, 11 angiogenesis 12 and ras transformation. 13 RHAMM is overexpressed in tumor cells and expression has not been found in healthy volunteers or in CD34 þ stem cells; these features favor RHAMM as a target for immunotherapy. We have previously described increased RHAMM expression in CLL patients and characterized an immunogenic human leukocyte antigen (HLA)-A2-restricted RHAMM-derived epitope (R3) as a potential target for immunotherapy in patients with CLL. 14 Recently, we described the increased expression of RHAMM in high-risk CLL patients (characterized by unmutated IgVH gene status as well as del11q and del17p). 15 Moreover, we showed that R3-primed CD8 þ T cells were able to lyse RHAMM þ CLL target cells, thereby providing additional validation of RHAMM as a preferred target for immunotherapy in CLL. 15 We also described encouraging results from a peptide vaccination trial based on R3, showing clinical as well as immunological responses in a heterogeneous group of hematological patients suffering from acute myeloid leukemia, myelodysplastic syndrome or multiple myeloma, 16 conditions in which RHAMM is also overexpressed. Therefore, we initiated a phase I clinical trial of RHAMM-derived R3 peptide vaccination in patients with CLL.
Six CLL patients completed the vaccination schedule and R3-specific CD8
þ T-cell immune responses were analyzed in conjunction with clinical parameters. Throughout vaccination, we also monitored changes in regulatory CD4 þ T cells (Tregs), which were reported to have a crucial role in the modulation of immune responses in CLL patients. 17, 18 Materials and methods
Patient characteristics
Six patients diagnosed with CLL at the Medical University of Lublin (Poland) were enrolled in this study. Approval was granted by the Local Ethics Committee (no. KE-025411/2006) and written informed consent was obtained in all cases. Clinical characteristics are detailed in Table 1 . All patients were at an early stage of disease (Binet A), previously untreated and presented no autoimmune events. Tests for RHAMM expression by reverse transcription PCR and for HLA-A2 expression by flow cytometry were positive in all cases.
Samples from patients with CLL
Peripheral blood mononuclear cells from CLL patients were isolated by standard Ficoll (Biochrom, Berlin, Germany) separation techniques and stored for both RNA preparation at À80 1C and for cellular assays in liquid nitrogen. Molecular genetics characterization, including the detection of genomic aberrations by fluoresence in situ hybridization and the determination of IgVH status by sequencing, as well as the determination of ZAP-70 expression were performed as previously described.
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Study design
Patients received 300 mg RHAMM-derived HLA-A2-restricted R3 peptide (ILSLELMKL, residues 165-173; Merck Biosciences/ Clinalpha, Laufingen, Switzerland) dissolved in dimethyl sulfoxide (Sigma-Aldrich, Munich, Germany) and emulsified in a mixture of incomplete Freund's adjuvant (IFA) (ISA-51, Montanide; Seppic, Paris, France) and phosphate-buffered saline (Biochrom) on day 3. As an adjuvant, 100 mg granulocytemacrophage colony stimulating factor (GM-CSF, Leukine; Berlex, Richmond, CA, USA) was administered subcutaneously four times on days 1-5 ( Figure 1 ). This vaccination schedule was repeated four times at biweekly intervals. The primary aim of this phase I clinical trial was to test the safety and feasibility of R3 peptide vaccination in CLL patients. Secondary aims were to evaluate the specific T-cell immune responses to R3 peptide and changes in other T-cell populations, as well as to assess the influence of R3 peptide vaccination on hematological status.
Assessment of clinical responses and toxicity of R3 peptide vaccination
All patients were examined before and after the administration of each peptide vaccination, and at 1, 3, 6 and 12 months after Figure 1 Schematic view of study protocol. Patients received 300 mg RHAMM-derived HLA-A2-restricted R3 peptide (ILSLELMKL, residues 165-173) in incomplete Freund's adjuvant on day 3. As an adjuvant, 100 mg GM-CSF was administered four times subcutaneously once daily from day -2 at a biweekly interval. Peripheral blood samples were collected at the start of each course on day -2, before the first dose of GM-CSF. All patients were examined clinically before and after the administration of each peptide vaccination, and at 1, 3, 6 and 12 months after the last dose of R3 peptide. Arrows indicate the time points of vaccination. 
Evaluation of T-cell subpopulations
Staining for the surface antigens CD3, CD4, CD8, CD25 and CD69 was performed using the relevant fluorochrome-conjugated monoclonal antibodies (mAbs; all from BD Biosciences, San Diego, CA, USA) according to the manufacturer's recommendations. To characterize Tregs, cells were first surface stained for CD3, CD4, CD25 and CD127, then permeabilized, blocked with rat serum and stained with anti-FoxP3 rat mAb according to the manufacturer's protocol (eBiosciences, San Diego, CA, USA). After intracellular staining, cells were washed twice and FoxP3 expression was analyzed in CD4 þ CD25 hi CD127 lo T lymphocytes by flow cytometry (Supplementary Figure 1) .
Assessment of T-cell responses ex vivo
To evaluate specific T-cell responses ex vivo, cells were stained with tetrameric complexes of HLA-A2/R3 peptide (R3-tetra; Lausanne Branch of the Ludwig Institute for Cancer Research, Lausanne, Switzerland) conjugated to phycoerythrin (PE) for 30 min at 37 1C. 21 Thereafter, cells were washed and stained with the directly conjugated mAbs, CD3*APC-Cy7, CD8*PerCP, CD45RA*APC and CCR7*PE-Cy7, to discriminate the differentiation status of R3-specific CD8 þ T cells. After a further wash, cells were fixed with 1% formaldehyde (Sigma-Aldrich) and analyzed using flow cytometry. In all cases, at least 1 00 000 events were collected using a FACSAria flow cytometer (BD Immunocytometry Systems, San Diego, CA, USA). Analysis was performed on CD3 þ CD8 þ cells within a tightly defined lymphocyte gate based on forward size scatter (FSC) vs side size scatter (SSC) properties.
MLPC
Thawed peripheral blood mononuclear cells were washed twice and subsequently enriched for CD8 þ T cells using magnetic beads and MACS technology (Miltenyi, Bergisch-Gladbach, Germany); a purity of 95% was achieved as assessed by flow cytometry. Mixed lymphocyte peptide culture (MLPC) was performed for influenza matrix peptide and R3 as previously described. 14 
IFN-g and granzyme B ELISpot assays
After 14 days of MLPC, enzyme-linked immunosorbent spot (ELISpot) assays for interferon (IFN)-g (Mabtech AG, Nacka, Sweden) and granzyme B (BD Biosciences) were performed as previously described 22 to determine specific release of these factors by R3-primed CD8 þ T lymphocytes in response to R3 peptide-pulsed T2 target cells. These assays were performed as recommended by the Cancer Immunotherapy (http://www. c-imt.org) Monitoring Panel, in which our institutions take part. 23 
Assessment of T-cell responses after pre-stimulation
As expected, the frequencies of R3-specific CD8 þ T cells measured ex vivo were very low (o0.01%) and we were unable to analyze them reliably in terms of signal/noise discrimination. Therefore, R3-specific CD8 þ T cells were amplified by MLPC as described above before further analyses. In these cultures, the frequencies of R3-specific CD8 þ T cells were determined at day 14 by staining with R3-tetra (Ludwig Institute for Cancer Research). In addition, we assessed peptide-specific degranulation concurrently on the basis of CD107a mobilization (Supplementary Figure 2) CrO 4 for 2 h as previously described, 22 and used as targets in cytotoxicity assays. In some experiments, 10 mg/ml major histocompatibility complex class I (MHC I)-blocking mAb (clone W6/32; Abcam, Cambridge, UK) was added to prove that specific lysis was MHC I restricted; a corresponding isotypematched mAb (Abcam) was used in parallel experiments for control purposes.
Statistical analysis
Results from enzyme-linked immunosorbent (in duplicates) and ELISpot assays (in triplicates) assays are shown as mean values±s.d. All other results are presented as median values± range. The Spearman's rank test was used to evaluate the correlation between T-cell subpopulations and serum cytokine levels.
Results
Immunological responses and vaccine-induced changes in the immune system
In five of six patients, we detected a substantial increase (4100%) in CD8 þ T cells specific for the R3 peptide based on staining of MLPC-amplified cultures with the cognate tetramer after the first dose of vaccine. These R3-specific CD8 þ T-cell responses were confirmed by IFN-g ELISpot assays in four of five available patients (Table 1 Figure 2a1 shows an increase in the frequency of R3-tetra þ CD8 þ T cells from 0.1 to 0.9% after the first vaccination for Patient no. 1, who responded clinically as defined by WBC reduction of 420% during the course of vaccination. In contrast, Patient no. 2, who did not respond clinically to vaccination, exhibited less impressive increases in the frequency of R3-tetra þ CD8 þ T cells during vaccination (Figure 2b1 ). We further analyzed these patients for the expression of CD107a, a marker of degranulation, in response to antigen encounter. The results displayed in Figure 2a2 for Patient no. 1 show high expression levels of CD107a before vaccination (84.2% of R3-tetra þ CD8 þ T cells); this increased further during vaccination to 92.5%. Conversely, only 47% of R3-tetra þ CD8 þ T cells from Patient no. 2 ( Figure 2b2 ) were initially positive for CD107a; this percentage increased after the first dose of the peptide vaccine to 75%, but later decreased to 57, 47 and 62% after the second, third and fourth doses, respectively. In line with these data, the IFN-g ELISpot results for Patient no. 2 revealed an increase in R3-specific CD8 þ T cells after the first vaccination that was not sustained after further doses of the R3 peptide vaccine; indeed, fewer R3-specific CD8 þ T cells were detected after the third and fourth doses than were present before vaccination (6.6 ± 1.1, 1.3 ± 0.6 and 3.3 ± 2 spots per 5 Â 10 4 CD8 þ cells±s.d. before vaccination, after the third dose and after the fourth dose, respectively; Figure 3b ). In contrast, Patient no. 1 exhibited increased numbers of functional R3-specific CD8 þ T cells in IFN-g ELISpot assays during the course of vaccination (Figure 3a) . We further analyzed the frequencies of regulatory T cells (Tregs) throughout the vaccination period. Both patients experienced increased levels of Tregs after the first vaccination. However, in Patient no. 1 (Figure 2a3 ), a moderate initial frequency of Tregs (2.5% of CD4 þ T cells) failed to expand substantially (2.9%; Figure 2a3 ); this contrasted with Patient no. 2, in whom a baseline Treg frequency of 3.6% before vaccination expanded to 9.1% after the first and 9.6% after the second dose of the R3 vaccine (Figure 2b3 ). We also examined the early activation marker CD69 and the late activation marker CD25. In Patient no. 1, we observed increased activation levels in both CD8 þ and CD4 þ T-cell subsets after the first vaccination (Figures 4a1 and a2) . Patient no. 2 exhibited high initial levels of activation in the CD4 þ T-cell subset that did not change substantially after vaccination ( Figure 4b1) ; furthermore, no increase in activation status was observed in the CD8 þ T-cell population (Figure 4b2 ). 
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Longitudinal tetramer data, together with analyses of Treg frequencies and WBC values, are shown for all patients in Figure 5 . In general, R3-tetra þ CD8 þ T-cell frequencies in MLPCamplified cultures increased during the course of vaccination in all patients ( Figure 5 ). The median Treg frequency in our cohort was 4.22% (range: 2.5-8%), which is consistent with recent studies that report increased frequencies of Tregs in CLL. 18, 24 There was no significant difference in Treg frequencies between clinical responders and nonresponders (median 6.12 vs 3.7%). Vaccination was associated with increased Treg frequencies in four patients; two were responders and two were nonresponders. In the two additional patients, both of whom were clinical responders, Treg frequencies either remained stable (Patient no. 1) or even declined (Patient no. 5) with repeated vaccination. There were no detectable correlations between the numbers of R3-tetra þ CD8 þ T cells, Treg frequencies and WBC values.
Toxicity of peptide vaccination
Six patients completed the course of four vaccinations and all were evaluated. Only mild side effects, including Common Toxicity Criteria grade 1 (CTC I1) erythema and induration of the skin at the site of injection, were observed after R3 peptide vaccination. Routine clinical examinations and laboratory tests specified in the Materials and methods section failed to show any evidence of therapy-related toxicity. No signs of autoimmunity were observed during or after vaccination.
Clinical responses to R3 peptide vaccination
Clinical responses were assessed by detailed physical examination and laboratory-based evaluation of changes in the peripheral blood before and after vaccination, as described in the Materials and methods section. Four of six patients (Patients no. 1, no. 3, no. 4 and no. 5) responded to the vaccine, evidenced by a reduction in WBC during treatment. Although these changes did not meet the National Cancer Institute response criteria, 20 we defined a reduction in WBC of 420% during the course of vaccination as a clinical response (Table 1 ). In contrast, the initial WBC of 16. 
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K Giannopoulos et al dropped to 16.4 g/l after the last dose of peptide. Patient no. 6 also exhibited a reduction in WBC, from 16.9 to 15.1 g/l, after the first dose of R3 peptide; however, this reduction was not maintained, with WBC values of 18.6, 20.1 and 20 g/l after the second, third and fourth doses of R3 peptide, respectively. These two patients were therefore classified as nonresponders based on our criteria. Patient details, immunological parameters and hematological responses are summarized in Table 1 .
MHC I-restricted lysis of CLL cells by R3-specific CD8
þ
T lymphocytes
By ELISpot analysis, we detected an increased number of R3-specific CD8 þ T cells that were able to secrete IFN-g as well as granzyme B in response to vaccination (Patients no. 1, no. 2, no. 4 and no. 6; Table 1, Figure 5 and data not shown). Further, the lytic potential of these R3-specific CD8 þ T cells was shown by CD107a mobilization (Figure 2 ). When these CD8 þ T cells were studied in standard 51 Cr release assays, effective lysis of autologous CLL cells at high effector/target (E/T) ratios was observed ( Figure 6 ); in contrast, K562 cells and T2 cells lacking either RHAMM or HLA-A2 expression were not lysed above background levels. As a positive control, T2 cells pulsed with R3 peptide were used to show peptide specificity. In addition, mAbbased MHC I blockade showed that the observed peptidespecific lysis was MHC I restricted ( Figure 6 ). At the highest E/T ratio of 20:1, R3-specific lysis was reduced from 51% in the presence of the isotype control mAb to 23% in the presence of RHAMM-R3 peptide vaccination in patients with CLL K Giannopoulos et al MHC I blockade. At lower E/T ratios, MHC I blockade completely abrogated R3-mediated target cell lysis.
Discussion
In this study, six patients with CLL expressing both RHAMM and HLA-A2 were vaccinated with the HLA-A2-restricted RHAMMderived peptide R3 four times at biweekly intervals. No severe adverse events greater than CTC I1 skin toxicity were observed. Thus, vaccination with an immunodominant peptide derived from a tumor antigen emulsified in IFA with concomitant administration of GM-CSF is safe and feasible in patients with CLL. Emulsification in IFA prevents peptide degradation in the subcutis and induces a semi-inflammatory microenvironment; GM-CSF attracts T cells and enhances immune responses to peptide vaccination. 25 The primary aim of this study was to induce immune responses in CLL patients vaccinated with four doses of the RHAMM-derived R3 peptide. This aim was achieved in five of six patients as determined by tetramer staining and further confirmed functionally in four of five patients using ELISpot assays. Moreover, a good concordance between these immunomonitoring methods was observed. However, the assays were performed after two rounds of pre-stimulation in mixed lymphocyte peptide cultures, suggesting that observed immune responses were limited. Interestingly, we observed some hematological changes during vaccination in this small group of six patients. Four patients improved hematologically during the 8-week vaccination course, with WBC reductions of at least 20%. It is possible that greater beneficial effects might be observed with longer and more intensive vaccination schedules, perhaps with the inclusion of MHC II-restricted epitopes to induce concomitant T-cell help.
Peptide vaccination induced dynamic changes in several lymphocyte subpopulations, including Tregs. Recently, we reported that increased frequencies of Tregs in patients with CLL can abrogate specific T-cell responses against tumorassociated antigens, including RHAMM. 18 Accordingly, one might expect that patients with higher Treg frequencies before vaccination might exhibit impaired responses to vaccination. However, in this study, we did not find any correlations between initial Treg frequencies and either immunological or clinical responses. Indeed, during the course of vaccination, we found increased Treg frequencies in two of four evaluated clinical responders. On the one hand, Tregs induced by the tumor itself or by the tumor environment might represent the main obstacle to effective cancer vaccination. On the other hand, Tregs are generated to dampen every successful immune response. 26 Therefore, one might speculate that the effective induction of tumor-associated antigen-specific immune responses could result in the amplification of Tregs. Treg elimination or modulation could be proposed as a strategy to enhance vaccine potency. Agents that target Tregs, such as the two promising CTLA-4-specific mAbs ipilimumab and tremelimumab, 27, 28 could be added to enhance the efficacy of peptide vaccination. 29 It is interesting that Patient no. 2, who showed an increase in Treg frequency during vaccination and did not respond clinically, initially exhibited high levels of CD25 expression in the CD4 þ T-cell compartment; in contrast, two of three responders exhibited increased CD25 levels in response to vaccination. High CD25 expression and the production of interleukin-2 in response to antigen might facilitate the generation of Tregs. 30 Accordingly we observed a correlation between interleukin-2 serum levels and the frequency of Tregs (data not shown). Leukemia-associated antigens could represent one target for immunotherapy; however, in CLL, immunotherapy could also be directed against leukemia-specific targets represented by immunoglobulin idiotype (Id). Id displayed on the surface of B cells constitutes a clonal marker of B-malignancy as well as a patient-specific antigen. Several studies have confirmed the biological efficacy of anti-Id vaccination. However, three randomized clinical trials have recently failed to achieve their main end points for reasons that are probably unrelated to vaccination. 31 Most clinical studies on Id vaccination have shown a substantial correlation between induction of an Id-specific immune response and improvement of clinical outcome. 32 Another imunotherapeutical approach aims to improve leukemia antigen presentation. Dendritic cells (DCs) as professional antigen-presenting cells can be generated from the blood of CLL patients. 33, 34 Our group has vaccinated CLL patients with autologous and allogeneic DC, and has observed immunological and, to some extent, hematological responses. 35, 36 Further clincial trials should combine several approaches such as vaccination with leukemia-associated antigen-derived epitope peptides, DC, DNA-encoding Id 37 as well as depletion of Tregs.
In summary, we have shown in a limited patient cohort that peptide vaccination in CLL patients is safe and can induce to some extent immune responses against the tumor antigen RHAMM. Furthermore, in this phase I clinical trial, there was evidence of hematological benefit associated with R3 peptide vaccination.
